Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 14/20 | 0.69 |
| ▸ | CDK9 | P50750 | 14/20 | 0.69 |
| ▸ | CDK7 | P50613 | 14/20 | 0.69 |
| ▸ | CCNH | P51946 | 13/20 | 0.69 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.69 |
| ▸ | EGFR | P00533 | 3/20 | 0.69 |
| ▸ | CDK2 | P24941 | 12/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.67 |
| ▸ | CCNK | O75909 | 10/20 | 0.65 |
| ▸ | CDK12 | Q9NYV4 | 10/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.65 |
| ▸ | CDK13 | Q14004 | 3/20 | 0.62 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397482 | 1.00 | CCNT1 (0.69) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16655099 | 1.00 | CCNT1 (0.69) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL21397428 | 1.00 | CCNT1 (0.69) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL21397381 | 0.95 | EGFR (0.70) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16654856 | 0.94 | CCNT1 (0.65) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16665759 | 0.94 | CCNT1 (0.65) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16665623 | 0.90 | CDK7 (0.68) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16653869 | 0.90 | CCNT1 (0.64) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16654303 | 0.88 | CCNT1 (0.64) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL21397470 | 0.87 | CDK9 (0.68) | CCNT1CDK9CDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| EP-3057964-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058163-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057659-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | CCNT1 28/4885CDK9 8/4885CDK7 1/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CCNT1 33/4885CDK9 12/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.